|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure显示文摘In advanced heart failure(HF), chronic inotropic therapy with intravenous milrinone, a phosphodiesterase Ⅲ inhibitor, is used as a bridge to advanced management that includes transplantation, ventricular assist device implantation, or palliation. This is especially true when repeated attempts to wean off inotropic support result in symptomatic hypotension, worsened symptoms, and/or progressive organ dysfunction. Unfortunately, patients in this clinical predicament are considered hemodynamically labile and may escape the benefits of guidelinedirected HF therapy. In this scenario, chronic milrinone infusion may be beneficial as a bridge to introduction of evidence based HF therapy. However, this strategy is not well studied, and in general, chronic inotropic infusion is discouraged due to potential cardiotoxicity that accelerates disease progression and proarrhythmic effects that increase sudden death. Alternatively, chronic inotropic support with milrinone infusion is a unique opportunity in advanced HF. This review discusses evidence that long-term intravenous milrinone support may allow introduction of beta blocker(BB) therapy. When used together, milrinone does not attenuate the clinical benefits of BB therapy while BB mitigates cardiotoxic effects of milrinone. In addition, BB therapy decreases the risk of adverse arrhythmias associated with milrinone. We propose that advanced HF patients who are intolerant to BB therapy may benefit from a trial of intravenous milrinone as a bridge to BB initiation. The discussed clinical scenarios demonstrate that concomitant treatment with milrinone infusion and BB therapy does not adversely impact standard HF therapy and may improve left ventricular function and morbidity associated with advanced HF. | Abhishek Jaiswal Vinh Q Nguyen Thierry H Le Jemtel Keith C Ferdinand | 2016 | World Journal of Cardiology2016，8，7： | 4 |
| 2 | Diagnostic and therapeutic challenge in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure显示文摘 | Le Jemtel TH Paddeletti M Jelic S | 2007 | J Am Coll Cardiol2007，49，2： | 1 |
| 3 | Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure显示文摘 | Le Jemtel TH Padeletti M Jelic S | | 0，，02： | 1 |
| 4 | Inflammation,oxidative stress,and the vas-cular endothelium in obstructive sleep apnea显示文摘 | Jelie S Le Jemtel T H | | 0，，7： | 1 |
| 5 | Diagnostic usefulness of B-type natriuretic peptide and functional consequences of muscle alterations in COPD and chronic heart failure显示文摘 | Jelic S Le Jemtel TH | 2006 | Chest2006，130，4： | 1 |
| 6 | Effect of nesiri-tide(B-type natriuretic peptide)and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure:the PRECEDENT study显示文摘 | Burger A J Horton D P Le Jemtel T | 2002 | Am Heart J2002，144，6： | 1 |
| 7 | Diagnostic and thera- peutic challenges in patients with coexistent chronic ob- structive pulmonary disease and chronic heart failure 显示文摘 | Le Jemtel TH Padeletti M Jelic S | 2007 | J Am Coll Cardiol2007，49，2： | 1 |
| 8 | Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure显示文摘 | Le Jemtel TH Padeletti M Jelic S | 2007 | Journal of the American College of Cardiology2007，49，2： | 1 |
| 9 | Diagnostic and thera- peutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure显示文摘 | Le Jemtel TH Padeletti M Jelic S | 2007 | JACC2007，49，2： | 1 |
| 10 | Addition of Angiotensin II Receptor Blockade to Maximal Angiotensin-Converting Enzyme Inhibition Improves Exercise Capacity in Patients With Severe Congestive Heart Failure显示文摘 | Glenn Hamroff Stuart D. Katz Donna Mancini Ira Blaufarb Rachel Bijou Rajoo Patel Guillaume Jondeau Maria-Teresa Olivari Sylvia Thomas Thierry H. Le Jemtel | 1999 | Circulation1999，，8： | 1 |
| 11 | Sustained hemodynamic effects of an infusi on of nesiritide(human B-type natriuretic peptide)in heart failure:a randomized,double-blind,placebo-controlled clinical trial显示文摘 | Mills RM Le Jemtel TH Horton DP | 1999 | Am Coll Cardiol1999，34，： | 1 |
| 12 | Sustained hemodynamic effect of an infusion of nesiritide(human B-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial显示文摘 | Mills Rm Le Jemtel TH Horton DP | 1999 | J Am Coll Cardiol1999，34，： | 1 |
| 13 | Nesiritide is not associated with the proarrhythmic effects of dobutamine in the treatment of decompensated CHF: The PRECEDENT Study显示文摘 | Burger AJ Horton DP Elkayam U Le Jemtel TH | 1999 | J Card Fail1999，5，49： | 1 |
| 14 | Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure显示文摘 | Le Jemtel TH Padeletti M ]die S | 2007 | J Am Coll Cardiol2007，49，2： | 1 |
| 15 | Vascular Inflammation in Obesity and Sleep Apnea显示文摘 | Sanja Jelic David J. Lederer Tessa Adams Margherita Padeletti Paolo C. Colombo Phillip H. Factor Thierry H. Le Jemtel | 2010 | Circulation2010，，8： | 1 |
| 16 | Diagnostic and therapeutic challenges in patientswith coexistent chronic obstructive pulmonary disease and chronic heart failure 显示文摘 | Jemtel TH PadelettiM Jelic S | 2007 | J Am Coll Cardiol2007，49，2： | 1 |
| 17 | Inflammation, oxidative stress, and the vascular endothelium in obstructive sleep apnea显示文摘 | Jelic S Le Jemtel T H | 2008 | Trends Cardiovasc Med2008，18，7： | 1 |
| 18 | Inflmmation, oxidative stress and the vascular endothehum in obstructive sleep apnea显示文摘 | JELIC S LE JEMTEL T H | 2008 | Trends Card- iovasc Med2008，18，7： | 1 |
| 19 | Management of diastolic heart failure显示文摘 | Thierry H Jemtell L Talreja A | 2004 | Cardiorasc Med2004，5，14： | 1 |
| 20 | Management of diastolic heart fail- ure显示文摘 | Thierry H Jemtell L Talreja A | 2004 | Cardiorasc Med2004，5，14： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员